• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

    5/15/25 4:01:00 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IPSC alert in real time by email
    • Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy
    • CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies
    • Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion™ 5.0 technology

    PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025.

    "We have made important progress focusing on pipeline programs with transformational potential in high-value commercial markets. In a recently held company webinar and at ASGCT, we showcased developmental progress with our preclinical pipeline, iPSC platform, and manufacturing capabilities, highlighting the potential for a pathway to developing iPSC-derived cell therapies at antibody-like scale. We are on track to initiate IND-enabling studies for our lead preclinical program, CNTY-308, in mid-2025," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. "For our clinical-stage pipeline, patient dosing is now underway in the U.S. for the CALiPSO-1 trial and, with expansion into Europe, we remain on track to deliver clinical data for CNTY-101 by the end of 2025. We look forward to building on this momentum and pursuing a disciplined approach across our pipeline to bring investigational cell therapies closer to patients and generate value for all our stakeholders."

    First Quarter 2025 and Recent Highlights

    CNTY-101 in Autoimmune Disease

    • Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for patients with B-cell-mediated autoimmune diseases.

    • Focus on CALiPSO-1 clinical trial expansion and patient recruitment: Five clinical trial sites in the U.S. are active with additional U.S. clinical trial sites expected to open in 2025. Site activation activities are underway in select European countries, with enrollment at these sites expected to initiate in the second half of 2025. The company's Clinical Trial Application (CTA) has been authorized in Germany, France, and Italy, providing important external validation of Century's approach to clinical studies with allogeneic iPSC-derived therapies.

    • CARAMEL IIT CTA authorized and study on track to commence in mid-2025: The CARAMEL investigator-initiated trial (IIT), a Phase 1/2 trial of CNTY-101 in patients with B-cell-mediated autoimmune diseases led by Professors Georg Schett and Andreas Mackensen and sponsored by the Friedrich-Alexander University Erlangen-Nürnberg, is expected to commence in mid-2025. The CTA has been authorized in Germany

    • Clinical data by end of 2025: The company remains on track to report clinical data for CNTY-101 by the end of 2025.



    CNTY-308 and Other Preclinical Programs

    • ASGCT presentations highlighting preclinical pipeline: At the ongoing American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, the company is presenting data on the company's emerging preclinical cell therapy pipeline for autoimmune diseases and cancer. The data from the poster presentation suggest certain engineering modifications to CAR-iT and CAR-iNK cells can improve the anti-tumor activity of iPSC-derived immunotherapies to withstand the immunosuppressive nature of the solid tumor microenvironment. The data from the oral presentation characterize the generation of allogeneic iPSC-derived targeted CD4+/CD8+ ab CAR-T cells with comparable function, in vivo proliferation, and tumor control to primary T cells, supporting their use for the development of scalable, accessible CAR-T cell therapies.

    • CNTY-308 on track to enter into IND-enabling studies in mid-2025: The company continues to expect to initiate Investigational New Drug (IND)-enabling studies with CNTY-308, a CD19-targeted CD4+/CD8+ ab CAR-iT cell therapy engineered with Allo-Evasion™ 5.0 as a potential treatment for B-cell-mediated autoimmune diseases and malignancies, in mid-2025.

    • Progressing early-stage development activities for iPSC-derived ab CAR-T cells in oncology and opportunities with non-immune effector cells in high-impact diseases: The company is advancing CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy intended for B-cell malignancies, and the company's first solid tumor CAR-iT investigational program exploiting nectin-4 CAR and other validated targets. Each of these programs is anchored by advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and is engineered with the company's proprietary immune evasion technology, Allo-Evasion™ 5.0, which is designed to enable holistic evasion of T cell, NK cell, and humoral immunity. In addition, the company is leveraging its deep expertise in selective iPSC differentiation to non-immune effector cells with opportunities to potentially accelerate in high-impact therapeutic areas where the company believes its technology and capabilities provide meaningful differentiation.



    First Quarter 2025 Financial Results

    • Cash Position: Cash, cash equivalents, and marketable securities were $185.8 million as of March 31, 2025, as compared to $220.1 million as of December 31, 2024. The company estimates its cash, cash equivalents, and investments will support operations into the fourth quarter of 2026.

    • Collaboration Revenue: Collaboration revenue generated through the company's collaboration, option, and license agreement with Bristol-Myers Squibb (the Collaboration Agreement) was $109.2 million for the three months ended March 31, 2025, compared to $0.9 million for the same period in 2024. The Collaboration Agreement was terminated effective March 12, 2025. As such, the company recognized $109.2 million of collaboration revenue for the quarter ended March 31, 2025. There will be no future collaboration revenues recognized under the Collaboration Agreement.

    • Research and Development (R&D) Expenses: R&D expenses were $26.6 million for the three months ended March 31, 2025, compared to $23.4 million for the same period in 2024. The increase in R&D expenses is most notably due to increased clinical trial costs and advancing of preclinical programs.

    • General and Administrative (G&A) Expenses: G&A expenses were $8.4 million for the three months ended March 31, 2025, compared to $8.7 million for the same period in 2024. The decrease was primarily due to a decrease in salary and benefit expense.

    • Net Income (Loss): Net income was $76.6 million for the three months ended March 31, 2025, compared to net (loss) of $28.1 million for the same period in 2024.



    About Century Therapeutics

    Century Therapeutics (NASDAQ:IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies with the potential to provide meaningful advantages over existing cell therapies. Century's genetically engineered, iPSC-derived cell therapy pipeline includes programs designed to address autoimmune diseases and cancers. Century believes its commitment to developing off-the-shelf cell therapies will expand patient access and provide an opportunity to advance the course of autoimmune disease and cancer care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our dependence on the success of our lead product candidate, CNTY-101; our ability to progress CNTY-101 through clinical development; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    For More Information:

    Century Therapeutics

    Morgan Conn, Ph.D.

    Chief Financial Officer

    [email protected]

    JPA Health

    Sarah McCabe

    [email protected]

    Century Therapeutics, Inc
    Condensed Balance Sheets
    (unaudited, in thousands)
           
      March 31,

     December 31,

    Assets 2025 2024
    Current Assets: $  $ 
    Cash and cash equivalents  51,865   58,441 
    Short-term investments  113,256   130,851 
    Prepaid expenses and other current assets  4,510   4,759 
    Total current assets  169,631   194,051 
    Property and equipment, net  59,532   62,141 
    Operating lease right-of-use assets, net  28,232   28,706 
    Long-term investments  20,713   30,818 
    Intangible assets  34,200   34,200 
    Other long-term assets  3,301   3,300 
    Total assets $315,609  $353,216 
           
    Liabilities, convertible preferred stock, and stockholders' equity   
    Current liabilities:      
    Accounts payable $3,573  $3,075 
    Accrued expenses and other liabilities  10,930   17,543 
    Deferred revenue, current  -   109,164 
    Total current liabilities  14,503   129,782 
    Operating lease liability, noncurrent  47,793   48,960 
    Contingent consideration liability  8,500   8,738 
    Deferred tax liability  4,374   4,374 
    Total liabilities  75,170   191,854 
    Stockholders' equity      
    Common stock  9   9 
    Additional paid-in capital  945,902   943,366 
    Accumulated deficit  (705,777)  (782,337)
    Accumulated other comprehensive loss  305   324 
    Total stockholders' equity  240,439   161,362 
    Total liabilities and stockholders' equity $315,609  $353,216 



    Century Therapeutics, Inc
    Condensed consolidated statements of operations
    (unaudited, in thousands, except share and per share amounts)
          
     Three Months Ended

     Three Months Ended

     March 31, 2025

     March 31, 2024

    Collaboration Revenue$109,164  $855 
          
    Operating Expenses     
    Research and development 26,580   23,421 
    General and administrative 8,408   8,743 
    Total operating expenses 34,988   32,164 
          
    Income (loss) from operations 74,176   (31,309)
          
    Interest income 2,422   3,237 
    Other income (expense), net (38)  11 
    Income (loss) before provision for income taxes 76,560   (28,061)
    Provision for income taxes -   (1)
    Net Income (loss)$76,560  $(28,062)
          
    Unrealized loss on investments (19)  (351)
    Foreign currency translation gain -   2 
    Comprehensive income (loss)$76,541  $(28,411)
          
    Net income (loss) per common share: Basic 0.89   (0.45)
    Net income (loss) per common share: Diluted 0.89   (0.45)
          
    Weighted average common shares outstanding: Basic 86,021,188   62,296,637 
    Weighted average common shares outstanding: Diluted 86,098,619   62,296,637 


    Primary Logo

    Get the next $IPSC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IPSC

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00Buy
    Rodman & Renshaw
    8/28/2023$28.00 → $5.00Overweight → Neutral
    JP Morgan
    12/27/2022$19.00Buy
    Chardan Capital Markets
    10/31/2022$15.00Buy
    Guggenheim
    10/10/2022$28.00Buy
    Canaccord Genuity
    5/23/2022$27.00Buy
    H.C. Wainwright
    5/12/2022Mkt Perform
    William Blair
    11/19/2021$33.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $IPSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Pfeiffenberger Brent sold $16,135 worth of shares (29,552 units at $0.55), decreasing direct ownership by 2% to 1,682,258 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/20/25 4:19:34 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operations Officer Farid Adrienne sold $563 worth of shares (1,024 units at $0.55), decreasing direct ownership by 0.41% to 250,693 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:50 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP Finance & Operations Carr Douglas sold $162 worth of shares (295 units at $0.55), decreasing direct ownership by 0.07% to 410,886 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:25 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Quimi Daphne bought $7,657 worth of shares (5,000 units at $1.53) (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      9/16/24 4:18:18 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IPSC
    SEC Filings

    See more
    • Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

      PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows: Abstract Number: 1380Title: C

      5/28/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion™ 5.0 technology PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripoten

      5/15/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

      PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows:

      4/28/25 4:30:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.

      SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      5/15/25 4:27:17 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Century Therapeutics, Inc. (0001850119) (Filer)

      5/15/25 4:15:54 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Century Therapeutics Inc.

      10-Q - Century Therapeutics, Inc. (0001850119) (Filer)

      5/15/25 4:15:56 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Century Therapeutics Inc.

      SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

      11/27/24 6:51:58 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 5:46:35 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 4:08:17 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00

      8/8/24 10:22:51 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics downgraded by JP Morgan with a new price target

      JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously

      8/28/23 7:15:43 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital Markets initiated coverage on Century Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $19.00

      12/27/22 7:45:12 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Leadership Updates

    Live Leadership Updates

    See more
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

      - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - Six posters to be presented at upcoming AACR Annual Meeting 2024 highlighting Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein en

      3/14/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

      - Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a who

      11/9/23 7:00:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Financials

    Live finance-specific insights

    See more
    • Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

      - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest

      5/9/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

      – Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – –   Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1

      12/9/23 12:00:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

      PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re

      12/6/23 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care